Total Neoadjuvant Therapy in Rectal Cancer: Multi-center Comparison of Induction Chemotherapy and Long-Course Chemoradiation Versus Short-Course Radiation and Consolidative Chemotherapy.
Complete response
Rectal cancer
Total neoadjuvant therapy
Journal
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
ISSN: 1873-4626
Titre abrégé: J Gastrointest Surg
Pays: United States
ID NLM: 9706084
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
received:
06
07
2022
accepted:
29
12
2022
medline:
28
4
2023
pubmed:
10
2
2023
entrez:
9
2
2023
Statut:
ppublish
Résumé
Total neoadjuvant therapy for locally advanced rectal cancer may include induction chemotherapy and chemoradiation or short-course radiotherapy and consolidative chemotherapy. Patients with clinical stage 2 or 3 rectal cancer who received induction chemotherapy followed by long-course chemoradiation at the University of Colorado (2016-2020) or short-course radiotherapy followed by consolidative chemotherapy at Washington University (2017-2020) were assessed. Eighty-four patients received induction chemotherapy and chemoradiation and 83 received short-course radiotherapy and consolidative chemotherapy. Among patients with complete re-staging evaluation, clinical complete response rates were similar, 49% (18/37) and 53% (44/83), respectively (p = 0.659). In the induction chemotherapy and chemoradiation group, 80% (n = 67) underwent surgery and 28% (n = 19) achieved a pathologic complete response. In the short-course radiotherapy and consolidative chemotherapy group, 44 (53%) patients underwent surgery and 11% (n = 5) had a pathologic complete response. Overall, a complete response was observed in 43% (n = 36) of patients who received induction chemotherapy and chemoradiation compared to 53% (n = 44) who received short-course radiotherapy and consolidative chemotherapy (p = 0.189). Perioperative outcomes were similar in patients who received induction chemotherapy and chemoradiation compared to short-course radiotherapy and consolidative chemotherapy: intraoperative complications (2% vs 7%), complete mesorectal specimen (85% vs 84%), anastomotic leak (9% vs 7%), organ/space infection (9% vs 5%), readmission (19% vs 21%), and reoperation (8% vs 9%), respectively (all p > 0.05). In patients with clinical stage 2 or 3 rectal cancer, total neoadjuvant therapy with either induction chemotherapy and chemoradiation or short-course radiotherapy followed by consolidative chemotherapy were associated with similar perioperative morbidity and complete response rates.
Sections du résumé
BACKGROUND
Total neoadjuvant therapy for locally advanced rectal cancer may include induction chemotherapy and chemoradiation or short-course radiotherapy and consolidative chemotherapy.
METHODS
Patients with clinical stage 2 or 3 rectal cancer who received induction chemotherapy followed by long-course chemoradiation at the University of Colorado (2016-2020) or short-course radiotherapy followed by consolidative chemotherapy at Washington University (2017-2020) were assessed.
RESULTS
Eighty-four patients received induction chemotherapy and chemoradiation and 83 received short-course radiotherapy and consolidative chemotherapy. Among patients with complete re-staging evaluation, clinical complete response rates were similar, 49% (18/37) and 53% (44/83), respectively (p = 0.659). In the induction chemotherapy and chemoradiation group, 80% (n = 67) underwent surgery and 28% (n = 19) achieved a pathologic complete response. In the short-course radiotherapy and consolidative chemotherapy group, 44 (53%) patients underwent surgery and 11% (n = 5) had a pathologic complete response. Overall, a complete response was observed in 43% (n = 36) of patients who received induction chemotherapy and chemoradiation compared to 53% (n = 44) who received short-course radiotherapy and consolidative chemotherapy (p = 0.189). Perioperative outcomes were similar in patients who received induction chemotherapy and chemoradiation compared to short-course radiotherapy and consolidative chemotherapy: intraoperative complications (2% vs 7%), complete mesorectal specimen (85% vs 84%), anastomotic leak (9% vs 7%), organ/space infection (9% vs 5%), readmission (19% vs 21%), and reoperation (8% vs 9%), respectively (all p > 0.05).
CONCLUSIONS
In patients with clinical stage 2 or 3 rectal cancer, total neoadjuvant therapy with either induction chemotherapy and chemoradiation or short-course radiotherapy followed by consolidative chemotherapy were associated with similar perioperative morbidity and complete response rates.
Identifiants
pubmed: 36759387
doi: 10.1007/s11605-023-05601-3
pii: 10.1007/s11605-023-05601-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
980-989Informations de copyright
© 2023. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.
Références
Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012;30(16):1926-33. https://doi.org/10.1200/jco.2011.40.1836 .
doi: 10.1200/jco.2011.40.1836
pubmed: 22529255
van Gijn W, Marijnen CA, Nagtegaal ID, Kranenbarg EM, Putter H, Wiggers T et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. The Lancet Oncology. 2011;12(6):575-82. https://doi.org/10.1016/s1470-2045(11)70097-3 .
doi: 10.1016/s1470-2045(11)70097-3
pubmed: 21596621
Chapman WC, Jr., Kim H, Bauer P, Makhdoom BA, Trikalinos NA, Pedersen KS et al. Total Neoadjuvant Therapy With Short-Course Radiation: US Experience of a Neoadjuvant Rectal Cancer Therapy. Dis Colon Rectum. 2022;65(2):198-206. https://doi.org/10.1097/dcr.0000000000001997 .
doi: 10.1097/dcr.0000000000001997
pubmed: 34990423
Morris EJA, Finan PJ, Spencer K, Geh I, Crellin A, Quirke P et al. Wide Variation in the Use of Radiotherapy in the Management of Surgically Treated Rectal Cancer Across the English National Health Service. Clinical oncology (Royal College of Radiologists (Great Britain)). 2016;28(8):522–31. https://doi.org/10.1016/j.clon.2016.02.002 .
Erlandsson J, Lörinc E, Ahlberg M, Pettersson D, Holm T, Glimelius B et al. Tumour regression after radiotherapy for rectal cancer - Results from the randomised Stockholm III trial. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2019;135:178-86. https://doi.org/10.1016/j.radonc.2019.03.016 .
doi: 10.1016/j.radonc.2019.03.016
pubmed: 31015165
Shi DD, Mamon HJ. Playing With Dynamite? A Cautious Assessment of TNT. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021;39(2):103-6. https://doi.org/10.1200/jco.20.02199 .
doi: 10.1200/jco.20.02199
pubmed: 33052753
Cercek A, Roxburgh CSD, Strombom P, Smith JJ, Temple LKF, Nash GM et al. Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer. JAMA oncology. 2018;4(6):e180071. https://doi.org/10.1001/jamaoncol.2018.0071 .
doi: 10.1001/jamaoncol.2018.0071
pubmed: 29566109
pmcid: 5885165
Bhatti AB, Waheed A, Hafeez A, Akbar A, Syed AA, Khattak S et al. Can induction chemotherapy before concurrent chemoradiation impact circumferential resection margin positivity and survival in low rectal cancers? Asian Pac J Cancer Prev. 2015;16(7):2993-8. https://doi.org/10.7314/apjcp.2015.16.7.2993 .
doi: 10.7314/apjcp.2015.16.7.2993
pubmed: 25854395
Petrelli F, Trevisan F, Cabiddu M, Sgroi G, Bruschieri L, Rausa E et al. Total Neoadjuvant Therapy in Rectal Cancer: A Systematic Review and Meta-analysis of Treatment Outcomes. Ann Surg. 2020;271(3):440-8. https://doi.org/10.1097/sla.0000000000003471 .
doi: 10.1097/sla.0000000000003471
pubmed: 31318794
Kasi A, Abbasi S, Handa S, Al-Rajabi R, Saeed A, Baranda J et al. Total Neoadjuvant Therapy vs Standard Therapy in Locally Advanced Rectal Cancer: A Systematic Review and Meta-analysis. JAMA Netw Open. 2020;3(12):e2030097. https://doi.org/10.1001/jamanetworkopen.2020.30097 .
doi: 10.1001/jamanetworkopen.2020.30097
pubmed: 33326026
pmcid: 7745099
Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK et al. NCCN Guidelines Insights: Rectal Cancer, Version 6.2020. J Natl Compr Canc Netw. 2020;18(7):806–15. https://doi.org/10.6004/jnccn.2020.0032 .
Bujko K, Wyrwicz L, Rutkowski A, Malinowska M, Pietrzak L, Kryński J et al. Long-course oxaliplatin-based preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2016;27(5):834-42. https://doi.org/10.1093/annonc/mdw062 .
doi: 10.1093/annonc/mdw062
Bahadoer RR, Dijkstra EA, van Etten B, Marijnen CAM, Putter H, Kranenbarg EM et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. The Lancet Oncology. 2021;22(1):29-42. https://doi.org/10.1016/s1470-2045(20)30555-6 .
doi: 10.1016/s1470-2045(20)30555-6
pubmed: 33301740
Garcia-Aguilar J, Patil S, Gollub MJ, Kim JK, Yuval JB, Thompson HM et al. Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2022;40(23):2546-56. https://doi.org/10.1200/jco.22.00032 .
doi: 10.1200/jco.22.00032
pubmed: 35483010
Smith FM, Wiland H, Mace A, Pai RK, Kalady MF. Clinical criteria underestimate complete pathological response in rectal cancer treated with neoadjuvant chemoradiotherapy. Dis Colon Rectum. 2014;57(3):311-5. https://doi.org/10.1097/DCR.0b013e3182a84eba .
doi: 10.1097/DCR.0b013e3182a84eba
pubmed: 24509452
Habr-Gama A, São Julião GP, Fernandez LM, Vailati BB, Andrade A, Araújo SEA et al. Achieving a Complete Clinical Response After Neoadjuvant Chemoradiation That Does Not Require Surgical Resection: It May Take Longer Than You Think! Dis Colon Rectum. 2019;62(7):802-8. https://doi.org/10.1097/dcr.0000000000001338 .
doi: 10.1097/dcr.0000000000001338
pubmed: 31188180
Garcia-Aguilar J, Chow OS, Smith DD, Marcet JE, Cataldo PA, Varma MG et al. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. The Lancet Oncology. 2015;16(8):957-66. https://doi.org/10.1016/s1470-2045(15)00004-2 .
doi: 10.1016/s1470-2045(15)00004-2
pubmed: 26187751
pmcid: 4670237
Lefevre JH, Mineur L, Kotti S, Rullier E, Rouanet P, de Chaisemartin C et al. Effect of Interval (7 or 11 weeks) Between Neoadjuvant Radiochemotherapy and Surgery on Complete Pathologic Response in Rectal Cancer: A Multicenter, Randomized, Controlled Trial (GRECCAR-6). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016;34(31):3773-80. https://doi.org/10.1200/jco.2016.67.6049 .
doi: 10.1200/jco.2016.67.6049
pubmed: 27432930
Marcello PW, Fleshman JW, Milsom JW, Read TE, Arnell TD, Birnbaum EH et al. Hand-assisted laparoscopic vs. laparoscopic colorectal surgery: a multicenter, prospective, randomized trial. Dis Colon Rectum. 2008;51(6):818–26; discussion 26–8. https://doi.org/10.1007/s10350-008-9269-5 .
Hassan I, You YN, Cima RR, Larson DW, Dozois EJ, Barnes SA et al. Hand-assisted versus laparoscopic-assisted colorectal surgery: Practice patterns and clinical outcomes in a minimally-invasive colorectal practice. Surg Endosc. 2008;22(3):739-43. https://doi.org/10.1007/s00464-007-9477-4 .
doi: 10.1007/s00464-007-9477-4
pubmed: 17704883
Overbey DM, Cowan ML, Hosokawa PW, Chapman BC, Vogel JD. Laparoscopic colectomy in obese patients: a comparison of laparoscopic and hand-assisted laparoscopic techniques. Surg Endosc. 2017;31(10):3912-21. https://doi.org/10.1007/s00464-017-5422-3 .
doi: 10.1007/s00464-017-5422-3
pubmed: 28281115
Prete FP, Pezzolla A, Prete F, Testini M, Marzaioli R, Patriti A et al. Robotic Versus Laparoscopic Minimally Invasive Surgery for Rectal Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Ann Surg. 2018;267(6):1034-46. https://doi.org/10.1097/sla.0000000000002523 .
doi: 10.1097/sla.0000000000002523
pubmed: 28984644
Jayne D, Pigazzi A, Marshall H, Croft J, Corrigan N, Copeland J et al. Effect of Robotic-Assisted vs Conventional Laparoscopic Surgery on Risk of Conversion to Open Laparotomy Among Patients Undergoing Resection for Rectal Cancer: The ROLARR Randomized Clinical Trial. Jama. 2017;318(16):1569-80. https://doi.org/10.1001/jama.2017.7219 .
doi: 10.1001/jama.2017.7219
pubmed: 29067426
pmcid: 5818805
Quirke P, Steele R, Monson J, Grieve R, Khanna S, Couture J et al. Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial. Lancet (London, England). 2009;373(9666):821-8. https://doi.org/10.1016/s0140-6736(09)60485-2 .
doi: 10.1016/s0140-6736(09)60485-2
pubmed: 19269520
pmcid: 2668948
Bonjer HJ, Deijen CL, Abis GA, Cuesta MA, van der Pas MH, de Lange-de Klerk ES et al. A randomized trial of laparoscopic versus open surgery for rectal cancer. The New England journal of medicine. 2015;372(14):1324-32. https://doi.org/10.1056/NEJMoa1414882 .
doi: 10.1056/NEJMoa1414882
pubmed: 25830422
Stevenson AR, Solomon MJ, Lumley JW, Hewett P, Clouston AD, Gebski VJ et al. Effect of Laparoscopic-Assisted Resection vs Open Resection on Pathological Outcomes in Rectal Cancer: The ALaCaRT Randomized Clinical Trial. Jama. 2015;314(13):1356-63. https://doi.org/10.1001/jama.2015.12009 .
doi: 10.1001/jama.2015.12009
pubmed: 26441180
Mechera R, Schuster T, Rosenberg R, Speich B. Lymph node yield after rectal resection in patients treated with neoadjuvant radiation for rectal cancer: A systematic review and meta-analysis. European journal of cancer (Oxford, England : 1990). 2017;72:84–94. https://doi.org/10.1016/j.ejca.2016.10.031 .
Chan DKH, Tan KK. Lower lymph node yield following neoadjuvant therapy for rectal cancer has no clinical significance. J Gastrointest Oncol. 2019;10(1):42–7. https://doi.org/10.21037/jgo.2018.10.02 .
Billakanti R, Seshadri RA, Soma S, Makineni H, Sundersingh S. Lymph Node Harvest After Neoadjuvant Treatment for Rectal Cancer and Its Impact on Oncological Outcomes. Indian J Surg Oncol. 2020;11(4):692-8. https://doi.org/10.1007/s13193-020-01162-y .
doi: 10.1007/s13193-020-01162-y
pubmed: 33281409
pmcid: 7714796